ReviewPediatric clinics of North America2021
COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials.
Review in Pediatric clinics of North America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06646744 (Safety Study About the mRNA Vaccines Against COVID-19 in Pediatric Patients), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety Study About the mRNA Vaccines Against COVID-19 in Pediatric Patients (PEDIVACOV-HCSC)
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence and clinical presentation of long COVID in children: a systematic review.European journal of pediatrics · 2022Pooled it
- Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 - 21 years old: A Systematic Review and Meta-analysis.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Pooled it
- Children aged 0-14 years had a far lower mortality risk during the entire COVID-19 pandemic in four major industrial countries: an observational study.European journal of pediatrics · 2024Observational
- Side effects of COVID-19 vaccines in paediatric patients: a review systematic and meta-analysis protocol.BMJ open · 2024Article
- Safety and Tolerability of Remdesivir in Infants and Children with COVID-19.Indian journal of pediatrics · 2023Article
- Epidemiology of COVID-19 among Children and Adolescents in Sudan 2020-2021.Epidemiologia (Basel, Switzerland) · 2023Article
- Article
- Younger age is associated with cardiovascular pathological phenotype of severe COVID-19 at autopsy.Frontiers in medicine · 2023Article
- Explore the attitudes of children and adolescent parents towards the vaccination of COVID-19 in China.Italian journal of pediatrics · 2022Article
- Mendelian randomization study on the causal effects of COVID-19 on childhood intelligence.Journal of medical virology · 2022Article
- A COVID-19 primer for primary care clinicians.Current problems in pediatric and adolescent health care · 2022Article
- Long-Term Complications of COVID-19 Infection in Adolescents and Children.Current pediatrics reports · 2022Review
- Unfolding the Mild to Moderate Short-Term Side Effects of Four COVID-19 Vaccines Used in Bahrain: A Cross-Sectional Study.Vaccines · 2021Article
- Progress in the Diagnosis and Treatment of COVID-19 in Children: A Review.International journal of general medicine · 2021Review
- The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment.Journal of global healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Children usually present with milder symptoms of COVID-19 as compared with adults. Supportive care alone is appropriate for most children with COVID-19. Antiviral therapy may be required for those with severe or critical diseases. Currently there has been a rapid development of vaccines globally to prevent COVID-19 and several vaccines are being evaluated in children and adolescents. Currently, only the Pfizer-BioNTech messenger RNA vaccine is approved for emergency authorization use in the pediatric population ages 16 years and older.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.